Replimune Group, Inc. (NASDAQ:REPL) Insider Sells $64,093.12 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,952 shares of the business’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the transaction, the insider now owns 146,933 shares in the company, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Replimune Group Stock Down 4.7%

REPL opened at $8.35 on Friday. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market cap of $643.08 million, a price-to-earnings ratio of -2.72 and a beta of 0.68. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company’s 50-day moving average price is $8.63 and its two-hundred day moving average price is $11.21.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company earned ($0.25) EPS. As a group, equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in shares of Replimune Group by 42.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company’s stock valued at $9,425,000 after purchasing an additional 232,822 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Replimune Group in the fourth quarter valued at approximately $543,000. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Swiss National Bank raised its position in shares of Replimune Group by 57.4% in the fourth quarter. Swiss National Bank now owns 103,700 shares of the company’s stock valued at $1,256,000 after purchasing an additional 37,800 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Replimune Group by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock valued at $2,113,000 after purchasing an additional 11,893 shares during the period. Institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REPL. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright boosted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.